.Kaufmann, P., Pariser, A. R. & Austin, C. From scientific discovery to procedures for unusual diseasesu00e2 $" the view coming from the National Center for Advancing Translational Sciencesu00e2 $" Workplace of Rare Diseases Study. Orphanet J. Rare Dis. 13, 196 (2018 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T. A phone call to upper arms against ultra-rare illness. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Vockley, J. et al. The progressing function of health care geneticists in the era of genetics treatment: a seriousness to prepare. Genet. Medication. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide therapy for a rare hereditary condition. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kim, J. et al. A framework for customized splice-switching oligonucleotide therapy. Structure 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lima, W. F. et cetera. Individual RNase H1 discriminates in between refined variants in the design of the heteroduplex substratum. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X.-H. Antisense innovation: a review and prospectus. Nat. Rev. Medicine Discov. 20, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lee, J.-R. et cetera. Afresh anomalies in the motor domain of KIF1A trigger intellectual disability, spastic paraparesis, axonal neuropathy, as well as cerebellar degeneration. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Boyle, L. et cetera. Genotype as well as defects in microtubule-based mobility connect with clinical seriousness in KIF1A-associated nerve ailment. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Motor protein KIF1A is essential for hippocampal synaptogenesis as well as knowing augmentation in a developed atmosphere. Nerve cell 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Guo, Y. et al. A rare KIF1A missense anomaly enriches synaptic functionality as well as improves seizure task. Face. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kaur, S. et cetera. Development of the phenotypic spectrum of de novo missense alternatives in kinesin family member 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Canivez, G. L. & McGill, R. J. Element construct of the Differential Potential Scales-Second Version: exploratory as well as hierarchical aspect analyses along with the center subtests. Psychol. Evaluate. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Epstein, A. et cetera. Content recognition of the lifestyle inventoryu00e2 $" disability. Childcare Health And Wellness Dev. Forty five, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Lek, M. et al. Analysis of protein-coding genetic variety in 60,706 human beings. Attributes 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medicine Products for Drastically Exhausting or even Dangerous Illness: Professional Referrals (United States Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Entries for Personalized Antisense Oligonucleotide Medicine Products: Management as well as Procedural Suggestions Advice for Sponsor-Investigators (United States Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Drug Treatment Articles for Personalized Antisense Oligonucleotide Medicine Products for Seriously Devastating or even Deadly Illness: Chemical Make Up, Production, as well as Controls Recommendations, Support for Sponsor-Investigators (United States Fda, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Seriously Debilitating or even Deadly Conditions Support for Sponsor-Investigators (US Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.